A tumefactive demyelinating lesion in a person with MS after five years of fingolimod

•Description of the development of tumefactive demyelinating lesion under fingolimod.•There has been an increasing number of reports describing the above.•This has not been seen in other immune modifying drugs used in multiple sclerosis. A 38-year-old man with relapsing remitting multiple sclerosis...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis and related disorders 2020-05, Vol.40, p.101978, Article 101978
Main Authors: Jeung, L., Smits, L.M.G., Hoogervorst, E.L.J., van Oosten, B.W., Frequin, S.T.F.M.
Format: Article
Language:English
Subjects:
Adult
Brain - diagnostic imaging
Brain - pathology
Fingolimod Hydrochloride - adverse effects
Humans
Immunosuppressive Agents - adverse effects
Magnetic Resonance Imaging
Male
Multiple Sclerosis, Relapsing-Remitting - drug therapy
Multiple Sclerosis, Relapsing-Remitting - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Description of the development of tumefactive demyelinating lesion under fingolimod.•There has been an increasing number of reports describing the above.•This has not been seen in other immune modifying drugs used in multiple sclerosis. A 38-year-old man with relapsing remitting multiple sclerosis (RRMS) developed a tumefactive demyelinating lesion (TDL) after being clinically and radiologically stable on fingolimod for the last five years. TDLs in MS tend to occur early on in the disease and are uncommon in longstanding MS. Compared to other immune modifying drugs used in MS, there is a relatively high and still increasing number of reports describing the development of TDL under treatment with fingolimod, suggesting a causal relation.
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2020.101978